Compare FTAI Aviation Ltd (FTAI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FTAI Aviation Ltd vs Vertex Pharmaceuticals Incorporated — how do they compare? FTAI Aviation Ltd trades at $171 (market cap $17.96B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.1× FTAI Aviation Ltd's market cap, and FTAI Aviation Ltd pays a 1.14% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| FTAI | VRTX | |
|---|---|---|
Market Cap | $17.96B | $128.16B |
Volume | 1,695,650 | 806,603 |
Sector | Industrials | Health |
52-Week High | $310.04 | $557.96 |
52-Week Low | $152.80 | $407.37 |
Typical Hold Time | 22 Days | 120 Days |
Enterprise Value | $21.07B | $122.29B |
Dividend Yield | 1.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $174.83, down 2.57% today, with a bearish technical signal. The company reported strong revenue growth to $2.51B in 2025 but missed EPS estimates for three consecutive quarters. Recent developments include a $500 million share repurchase program and a strategic acquisition of 27 Boeing aircraft, signaling aggressive expansion. Analyst consensus remains unanimously bullish with a $321.25 price target, despite negative operating cash flow and declining net income margins.
The outlook is mixed: robust institutional support and growth initiatives contrast with earnings misses and cash flow concerns. Key risks include execution of new ventures and sensitivity to aviation sector cycles. The stock offers significant upside if operational improvements materialize, but investors face volatility from quarterly performance gaps and macroeconomic pressures on the industry.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
